Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 7/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | HTR2A | P28223 | 2/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.43 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | METTL3 | Q86U44 | 2/20 | 0.38 |
| ▸ | METTL14 | Q9HCE5 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | DRD1 | P21728 | 1/20 | 0.36 |
| ▸ | HTR6 | P50406 | 4/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2691734 | 0.85 | NPC1 (0.43) | TAAR1SMN1; SMN2LOXL2NPC1ALDH1A1 | |
| SCHEMBL2945627 | 0.81 | NPC1 (0.41) | SMN1; SMN2NPC1ALDH1A1POLBMAPT | |
| SCHEMBL2760780 | 0.77 | NPC1 (0.43) | SMN1; SMN2NPC1ALDH1A1POLBMAPT | |
| SCHEMBL17372780 | 0.74 | SMN1; SMN2 (0.41) | SMN1; SMN2NPC1ALDH1A1POLBMAPT | |
| SCHEMBL25515910 | 0.74 | TAAR1 (0.48) | TAAR1SMN1; SMN2HTR2ACYP2A6NPC1 | |
| SCHEMBL24358125 | 0.73 | NPC1 (0.40) | TAAR1SMN1; SMN2CYP2A6NPC1ALDH1A1 | |
| SCHEMBL3670866 | 0.73 | KDM4E (0.40) | SMN1; SMN2NPC1ALDH1A1POLBMAPT | |
| SCHEMBL19682140 | 0.73 | ALDH1A1 (0.40) | TAAR1SMN1; SMN2NPC1ALDH1A1POLB | |
| SCHEMBL28195327 | 0.73 | METTL3 (0.42) | SMN1; SMN2NPC1ALDH1A1POLBMAPT | |
| SCHEMBL28813192 | 0.71 | AKR1B1 (0.48) | SMN1; SMN2NPC1ALDH1A1POLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240308999-A1 | INDOLIZINE COMPOUNDS FOR THE TREATMENT OF MENTAL DISORDERS OR MENTAL ENHANCEMENT | TACTOGEN INC (US) | 2024-09-19 | — | — | US | disclosed |
| EP-4426291-A1 | INDOLIZINE COMPOUNDS FOR THE TREATMENT OF MENTAL DISORDERS OR MENTAL ENHANCEMENT | Tactogen Inc. (US) | 2024-09-11 | — | — | EP | disclosed |
| WO-2023081306-A1 | INDOLIZINE COMPOUNDS FOR THE TREATMENT OF MENTAL DISORDERS OR MENTAL ENHANCEMENT | TACTOGEN INC (US) | 2023-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240308999-A1 | INDOLIZINE COMPOUNDS FOR THE TREATMENT OF MENTAL DISORDERS OR MENTAL ENHANCEMENT | PNMT, HTR5A, HTR4 | TAAR1 150/4885SMN1; SMN2 3186/4885HTR2A 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.